NCT01044316View on ClinicalTrials.gov

Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China

PHASE3CompletedINTERVENTIONAL
Enrollment

670

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

December 31, 2010

Conditions
Haemophilus Influenzae Type b (Hib) Infection
Interventions
BIOLOGICAL

Haemophilus influenzae type b (Hib) vaccine

Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.

Trial Locations (1)

Unknown

Hebei Province

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY